SCHEMBL374815

SCHEMBL374815

Oc1c(Cl)cc(F)cc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 8/20 0.58
TSHR P16473 6/20 0.58
CYP3A4 P08684 4/20 0.58
TTR P02766 3/20 0.58
RECQL P46063 3/20 0.58
ALDH1A1 P00352 2/20 0.58
THRB P10828 3/20 0.52
ALOX15 P16050 3/20 0.50
ALOX12 P18054 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
HIF1A Q16665 3/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C19 P33261 2/20 0.50
IDO1 P14902 1/20 0.50
CYP2C9 P11712 1/20 0.50
HPGD P15428 6/20 0.46
MAPK1 P28482 3/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA9 Q16790 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5399616 0.86 ERN1 (0.46) HSD17B10TSHRCYP3A4TTRRECQL
SCHEMBL102065 0.82 THRB (0.48) HSD17B10TSHRCYP3A4TTRRECQL
SCHEMBL5310503 0.82 IDO1 (0.43) HSD17B10TSHRCYP3A4TTRRECQL
SCHEMBL1684148 0.82 IDO1 (0.43) HSD17B10TSHRCYP3A4TTRRECQL
SCHEMBL7839561 0.82 PTGS1 (0.47) HSD17B10TSHRCYP3A4TTRRECQL
SCHEMBL2250088 0.82 IDO1 (0.43) HSD17B10TSHRCYP3A4TTRRECQL
Hydrochloric Acid SCHEMBL6267077 0.80 THRB (0.46) HSD17B10TSHRCYP3A4TTRRECQL
SCHEMBL22777763 0.80 HSD17B10 (0.61) HSD17B10TSHRCYP3A4TTRRECQL
SCHEMBL20871043 0.77 MEN1 (0.46) HSD17B10TSHRCYP3A4TTRRECQL
SCHEMBL3190669 0.77 IDO1 (0.40) HSD17B10TSHRCYP3A4TTRRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6989052-B1 Phase change ink printing process XEROX CORPORATION (US) 2006-01-24 US claimed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 US claimed
EP-1066269-B1 TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2005-05-11 EP claimed
US-20020115668-A1 Trisubstituted 1,3,5-triazine derivatives DAEYAERT FREDERIK FRANS DESIRE (BE) 2002-08-22 US claimed
EP-1066269-A1 TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS JANSSEN PHARMACEUTICA N.V. (BE) 2001-01-10 EP claimed
US-6150360-A ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE JANSSEN PHARMACEUTICA N.V. (BE) 2000-11-21 US claimed
WO-1999050256-A1 TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS JANSSEN PHARMACEUTICA N.V. (BE) 1999-10-07 WO claimed
JP-9087221-A None JP disclosed
US-20240360124-A1 Bromodomain Inhibitors ABBVIE INC. (US) 2024-10-31 US disclosed
CN-110774776-B Method of forming electrically conductive three-dimensional articles 施乐公司 2023-04-04 CN disclosed
EP-3599077-B1 METHOD OF FORMING CONDUCTIVE THREE-DIMENSIONAL ARTICLES XEROX CORP (US) 2022-02-16 EP disclosed
US-20220017511-A1 Bromodomain Inhibitors ABBVIE INC. (US) 2022-01-20 US disclosed
US-20210380595-A1 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS ARAXES PHARMA LLC (US) 2021-12-09 US disclosed
US-5116982-A Fluorination DOWELANCO (US) 1992-05-26 US disclosed
EP-0470669-A2 Preparation of fluorophenols, fluorohalophenols, N-acylfluoroanilines, and N-acylfluorohaloanilines DOWELANCO (US) 1992-02-12 EP disclosed
US-5053557-A PROCESS FOR PREPARING 2-CHLORO-4-FLUOROPHENOL SAGAMI CHEMICAL RESEARCH CENTER (JP) 1991-10-01 US disclosed
EP-0417720-A2 Process for preparing 2-chloro-4-fluorophenol SAGAMI CHEMICAL RESEARCH CENTER (JP) 1991-03-20 EP disclosed
US-4620042-A Preparation of 2-chloro-4-fluorophenol from 4-fluorophenol CENTRAL GLASS COMPANY, LIMITED (JP) 1986-10-28 US disclosed
EP-0017209-B1 SUBSTITUTED ALKYLAMMONIUM SALTS, THEIR PREPARATION AND USE IN PLANT GROWTH REGULATION BASF Aktiengesellschaft (DE) 1982-12-22 EP disclosed
US-4350518-A Plant growth regulating substituted alkylammonium salts BASF AKTIENGESELLSCHAFT (DE) 1982-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115668-A1 Trisubstituted 1,3,5-triazine derivatives XDH, CCR5, CXCR1 HSD17B10 1218/4885TSHR 656/4885CYP3A4 174/4885
US-20220017511-A1 Bromodomain Inhibitors BRD4, BRD3, BRD1 HSD17B10 2913/4885TSHR 2279/4885CYP3A4 2255/4885
US-20210380595-A1 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS KRAS, NRAS, G3BP2 HSD17B10 4629/4885TSHR 4148/4885CYP3A4 3748/4885
US-20240360124-A1 Bromodomain Inhibitors BRD4, BRD3, BRD1 HSD17B10 2913/4885TSHR 2279/4885CYP3A4 2255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.